NEW YORK (360Dx) – Immunodiagnostic Systems today announced a global deal to sell assay kits developed by Technogenetics under the IDS brand.
Technogenetics has developed a range of CE-marked CLIA automated assay kits for detecting and therapeutic monitoring of autoimmune and infectious diseases. The kits were developed for Immundiagnostic's IDS-iSYS Multi-Discipline Automated System, and under an earlier agreement, Immunodiagnostic was able to sell a limited number of the assays in a small number of European countries. Under the new 10-year deal, Immunodiagnostic will be able to sell the kits globally under the IDS brand.
Financial and other terms of the deal were not disclosed.
"We now have access to a further 50 assays in additional territories, which will complement our existing endocrinology portfolio and add to our competitive position as a result of the increased menu on the IDS-iSYS," Immunodiagnostic CEO Jaap Stuut said in a statement. "During the next financial year, we will focus on obtaining regulatory approval outside Europe for these assays and on driving further commercialization as soon as possible."
UK-based Immunodiagnostic develops and markets immunoassays and automated immunoanalyzer technologies with a focus on endocrinology. Technogenetics, headquartered in Milan, operates in the diagnostic research and biotechnology space and is part of the KHB Group, which is based in Shanghai.